Circadian Rhythm Interventions in Parkinson's Disease

Parkinson’s disease is typified by progressive dopaminergic neuronal loss in the substantia nigra, leading to hallmark motor deficits and a range of non-motor symptoms. Among the non-motor features, disrupted sleep–wake cycles and impaired circadian timing have emerged as both early markers and potential modulators of disease progression. Circadian rhythm interventions seek to restore synchrony between endogenous biological clocks and environmental cues by manipulating light exposure, pharmacological agents or behavioural scheduling. Such interventions aim to improve sleep architecture, ameliorate cognitive and mood disturbances, and perhaps slow neurodegenerative processes. Mechanistically, therapeutic strategies target retinal melanopsin pathways, the suprachiasmatic nucleus pacemaker and peripheral clock genes to adjust circadian phase and amplitude. Clinical trials and experimental models now offer evidence that personalised light regimes, exogenous melatonin administration and behavioural chronotherapy can stabilise rest–activity patterns, enhance restorative sleep stages and influence neurophysiological markers of circadian function. As research converges on the interplay between circadian health and dopaminergic signalling, interventions designed to bolster circadian robustness hold promise for addressing both symptomatic burdens and underlying disease biology.

Research from Nature Portfolio

Recent studies have shown that bright light therapy administered to patients receiving dopaminergic treatment can significantly improve subjective and objective measures of sleep quality by inducing phase shifts in melatonin secretion. Experimental work in ex vivo preparations of the suprachiasmatic nucleus reveals that chronic dopaminergic stimulation attenuates intrinsic clock gene oscillations at the single-cell level, a dysfunction reversible by timed light exposure. These findings support the clinical observation that light-induced restoration of circadian rhythmicity correlates with sleep improvement in Parkinson’s disease.

Circadian Rhythm Interventions in Parkinson's Disease publication trend

The graph below shows the total number of articles in circadian rhythm interventions in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Chronotype: An individual’s propensity for activity and alertness at particular times of day, often described as “morningness” or “eveningness”.

Melanopsin: A photopigment in intrinsically photosensitive retinal ganglion cells that mediates non-visual responses to light, including circadian entrainment.

Dim Light Melatonin Onset (DLMO): The timepoint at which endogenous melatonin levels begin to rise under low-light conditions, marking circadian phase.

Suprachiasmatic Nucleus (SCN): The primary circadian pacemaker located in the anterior hypothalamus that coordinates daily rhythms in physiology and behaviour.

Circadian Phase: The position within the approximately 24-hour circadian cycle, often referenced to physiological markers such as core temperature nadir or DLMO.

Sleep Architecture: The structure of sleep stages across a sleep period, including proportions of rapid eye movement (REM) and non-REM stages.

References

1. The intertwined relationship between circadian dysfunction and Parkinson's disease. Trends in Neurosciences (2024).
2. Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trial. EClinicalMedicine (2024).
3. Sleep and circadian rhythms in α‐synucleinopathies—Perspectives for disease modification. Acta Physiologica (2023).
4. Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration. Scientific Reports (2020).
5. Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease. Frontiers in Pharmacology (2021).